{"contentid": 488056, "importid": NaN, "name": "Data show alternative to hospital for some CABP patients", "introduction": "Nabriva Therapeutics has published a post-hoc analysis of data from the Phase III LEAP 2 study of oral antibiotic Xenleta (lefamulin).", "content": "<p>Nabriva Therapeutics (Nasdaq: NBRV) has published a post-hoc analysis of data from the Phase III LEAP 2 study of oral antibiotic Xenleta (lefamulin).</p>\n<p>The innovative infectious disease specialist published data showing the impact of an outpatient five-day regimen of the therapy, in The Journal of Emergency Medicine.</p>\n<p>Xenleta is the first intravenous and oral antibiotic with a novel mechanism of action approved by the US regulator in nearly two decades.</p>\n<p>In the trial, people with moderate to severe community-acquired bacterial pneumonia (CABP) responded well to treatment, with responses comparable to a range of existing antibiotic therapies.</p>\n<p>Approved by the US and European regulators in mid-2019, analysts forecast that Xenleta, which has the potential to save resources by avoiding costly hospital admissions, could bring in up to a quarter of a billion dollars at peak.</p>\n<p>However, launched in the runup to the coronavirus pandemic, sales of the product have thus far been unspectacular.</p>\n<p>The firm noted in a statement that, &ldquo;in light of the COVID-19 pandemic and the associated disruption to the healthcare industry, future sales amounts in 2021 are uncertain.&rdquo;</p>\n<h2>Trial commentary</h2>\n<p>Lead author Frank LoVecchio said: &ldquo;In the treatment of CABP, initiating appropriate empiric oral antimicrobial therapy in the outpatient setting can result in significant economic benefits and successful infection control.&rdquo;</p>\n<p>He added: &ldquo;This analysis suggests that patients who might be considered for hospital admission, either due to advanced age, comorbidities or difficult-to-treat pathogens, can be managed effectively as outpatients using a 5-day monotherapy course of oral Xenleta, as an alternative to fluoroquinolones.&rdquo;</p>", "date": "2021-03-16 15:56:00", "meta_title": NaN, "meta_keywords": "data, Xenleta, oral, antibiotic, CABP, published, hospital, analysis, show, post-hoc, Therapeutics, Phase, LEAP, study, Nabriva, patients, alternative, NBR", "meta_description": "Nabriva Therapeutics has published a post-hoc analysis of data from the Phase III LEAP 2 study of oral antibiotic Xenleta (lefamulin).", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-16 15:55:44", "updated": "2021-03-16 23:36:39", "access": NaN, "url": "https://www.thepharmaletter.com/article/data-show-alternative-to-hospital-for-some-cabp-patients", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "vials_dugs_biologic_report_test_big.jpg", "image2id": "vials_dugs_biologic_report_test_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Antibiotics, Infectious diseases", "topic_tag": "Drug Trial, Research", "geography_tag": "Austria, USA", "company_tag": "Nabriva Therapeutics", "drug_tag": "Xenleta", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-16 15:56:00"}